Appointment sheet
Mixed-phenotype acute leukaemia
Prepared with OnCo (onco.cc/prep/mixed-phenotype-acute-leukaemia/). Orientation, not medical advice; your team knows your case.
My details
Name
Date of appointment
Hospital and clinician
Who is coming with me
What I know, what is unclear, changes to discuss
Saved in this browserWhat I know so far
What is unclear to me
Changes since last time
My questions
8 on the sheetNewly diagnosed
- 1.What is my exact diagnosis, stage, and grade, and which tests established them?
- 2.Which biomarkers have been tested on my tumour (for example Flow cytometry: myeloperoxidase or monocytic markers with cytoplasmic CD3 or CD19 plus CD79a, CD22 or CD10, BCR::ABL1 and KMT2A rearrangement, Measurable residual disease after induction, Two distinct blast populations), and what were the results?
- 3.Which subtype is my cancer, and does that change the recommended treatment?
- 4.Is germline (inherited) genetic testing recommended for me or my family?
Induction
- 5.For my situation (induction), which of the standard options do you recommend and why?
- 6.Am I a candidate for Imatinib, Dasatinib, and what side effects should I expect?
Any stage
- 7.Would a second opinion at a high-volume centre change anything, and can you help arrange it?
- 8.What supportive care (symptom control, nutrition, exercise, mental health, financial help) is available from the start?
The words I may hear
- Allogeneic stem cell transplant (allo-SCT): Replacing a patient's blood system with a donor's: chemotherapy wipes out the marrow, donor stem cells rebuild it, and the donor's immune cells hunt down leftover leukaemia.
Tests and results to bring
Biomarker results to ask for: Flow cytometry: myeloperoxidase or monocytic markers with cytoplasmic CD3 or CD19 plus CD79a, CD22 or CD10, BCR::ABL1 and KMT2A rearrangement, Measurable residual disease after induction, Two distinct blast populations (bilineal).
Scans and tests linked to this cancer: MRD / molecular residual disease testing.
Bring copies of scan reports, pathology and blood results, and a list of every medicine and supplement.
The treatments I may be offered
- Induction: Acute lymphoblastic leukaemia-type induction in most patients; tyrosine kinase inhibitor for BCR::ABL1 disease; allogeneic transplant in first remission for adults and high-risk children. (Acute lymphoblastic leukaemia, Acute myeloid leukaemia, Imatinib, Dasatinib, Allogeneic stem cell transplant (allo-SCT), MRD / molecular residual disease testing)
From the standard of care recorded for this cancer; which apply depends on your stage and biomarkers. Ask which the team recommends and why.
Answers and next steps
Saved in this browserWhat I was told
Agreed next steps, dates and who to call